PTOSSIGNS (0.2-0)
Approved for use through 0.30/1/2009. OMB files 1.00-10
U.S. Patient and Trademark (nière; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information undex is commaine a valid UMB control number.

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/788,606-Conf. #9642
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	February 27, 2004
				First Named Inventor	Mary E. Brunkow
				Art Unit	1646
	(Use as many sh	eets as	s necessary)	Examiner Name	X. Xie
Sheet	1	of	1	Attorney Docket Number	31173/40002

		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Examiner Initials	Cite No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C149	Albertsen et al., "A physical map and candidate genes in the BRCA1 region on chromosome 17q12-21," Nature Genetics, 7:472-479 (1994).	Г
	C150	Balemans et al., "Localization of the Gene for Sclerosteosis to the van Buchem Disease-Gene Region on Chromosome 17q12-q21," Am. J. Hum. Genet., 64:1661-1669 (1999).	Γ
	C151	Chan et al., "A new paradigm in the treatment of osteoporosis: Wnt pathway proteins and their antagonists," Current Opinion in Investigational Drugs, 8(4):293-298 (2007).	
	C152	Expert Opinion from Dr. Catalina Lopez-Correa, dated March 6, 2009.	
	C153	Li et al., "Sclerostin Binds to LRP5/6 and Antagonizes Canonical Wnt Signaling," Jour. Blo. Chem., 280(20); 19883-19887 (2005).	
	C154	van Bezooijen et al., "Wnt but Not BMP Signaling Is Involved in the Inhibitory Action of Sclerostin on BMP-Stimulated Bone Formation," J. Bone. Miner. Res. 22:19-28 (2007).	
	C155	Written Submission of Eli Lilly & Company, dated March 9, 2009, Opposition to European Patent No. 1133558.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date

Considered

11/18/2009

Examiner

Signature

/Xiaozhen Xie/

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.